[Pseudolymphoma in patients with primary Sjogren's syndrome]. / Pseudochloniak u chorej z pierwotnym zespolem Sjögrena.

Sjögren's syndrome is an inflammatory autoimmune disease affecting primarily the exocrine glands. In the abscence of other autoimmune diseases it is classified as primary Sjögren's syndrome. Patients with primary syndrome have about 40 times higher relative risk of developing lymphoma then normal population, which offers a possibility to study malignant transformation's mechanisms in these patients. In the study we report a case of a woman with pseudolymphoma. The clinical diagnose used to be based on symptoms of proliferate disease, quetionnable histological evaluation and good response to steroids. Nowadays, applying advanced molecular techniques make it possible to diagnose lymphoma in labial salivary biopsy much earlier. It allows recognizing an incipient lymphoma in a group of patients with primary Sjögren's syndrome. Therefore so-called pseudolymphoma can usually be diagnosed as either benign or malignant lymphoproliferative lesions.

[Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate]. / Wstrzas toksyczno-septyczny w przebiegu rabdomiolizy u chorej leczonej fenofibratem.

Lipid disorders have been treated with fibrates for many years. Rhabdomyolysis is one of the side effects of these drugs. We report a case of a septic-toxic shock due to rhabdomyolysis in a 75-year old patient, who had been treated with fenofibrate for 2 years. This case shows necessity of the standard monitoring of aminotransferase, phosphocreatine kinase and creatinine levels during treatment with fibrates.

[A probe using isotretinoin for treatment of poorly differentiated leukemia]. / Próba zastosowania izotretynoiny w leczeniu bialaczki niskozróznicowanokomórkowej.

Isotretinoin (Roaccutane) was used in a patient with low differentiated cell leukemia. Poor general condition, very low blood cell count as well patient's lack of consent made chemotherapy impossible. The effect of isotretinoin treatment was full hematological and clinical remission. The general patient's condition did not require additional medication.

Evaluation of the antiemetic effect of domperidon in patients treated with cytostatic drugs.

Forty patients with various neoplastic syndromes received domperidon as a drug reducing nausea and vomiting. The drug prevents in the daily dose of 30 mg completely the occurrence of nausea and vomiting in 30% of the patients and in 58% considerably reduces their intensity. The dose of 60 mg abolishes nausea and vomiting in 60% of the patients and alleviates in 35%. The drug had been administered through the whole period of chemotherapy without any side effects which may be attributed to its antagonist action to dopamine.

[Evaluation of anti-emetic action of domperidone in patients treated with cytostatics]. / Ocena przeciwwymiotnego dzialania domperydonu u chorych leczonych cytostatykami.

Domperidone was administered to 40 patients with various neoplastic syndromes to prevent nausea and vomiting observed during previous courses of chemotherapy. It was found, that daily dose of 30 mg completely prevents nausea and vomiting in 30% of patients and significantly lowers such symptoms in further 58% of patients. An increase in a daily dose of 60 mg abolishes nausea and vomiting in 60%, and decrease their intensity in 35% of patients. Domperidone was administered orally during the whole period of chemotherapy without any adverse reactions related to its anti-dopamine actions.